Can Overseas Papers on Stem Cell Conditioned Media and Exosomes Be Directly Applied to Hair Regeneration Medicine in Japan? — Dr. Moriwaki Explains Three Blind Spots: Study Conditions, Product Specifications, and Conflicts of Interest2026.08.14

“Overseas papers report that exosomes and stem cell conditioned media promote hair growth.” More and more patients come to AVAN TOKYO Ginza after seeing such messages on social media and in advertisements. But translating the one-line summary “effective in an overseas study” directly into Japanese hair regeneration medicine is not as simple as it looks. When you consider how to read overseas conditioned media evidence, you meet three easily missed pitfalls: study conditions, product specifications, and conflicts of interest. In this article, Dr. Shin Moriwaki of AVAN TOKYO Ginza lays out an honest, patient-oriented framework for interpreting overseas hair-regeneration research.

Key Points of This Article

・Overseas conditioned media evidence is not necessarily verified with “the same product” and “the same protocol” used at your clinic.

・When the study population differs (ethnicity, age, hair loss type), the results cannot be transferred as-is to Japanese hair treatment.

・The preparations used in overseas papers are often not available in Japan under the identical specification.

・For sponsored research, the Conflict of Interest (COI) disclosure section should always be checked.

・When a treatment is recommended solely on the basis of “it worked overseas,” it is important to ask follow-up questions to confirm.

Why Overseas Conditioned Media Evidence Cannot Be Imported to Japan As-Is

Whether at the level of case reports, observational studies, or comparative trials — the three tiers of overseas research in the hair field — the stem cell conditioned media or exosome preparations used differ from facility to facility in cell source (umbilical cord, adipose, dental pulp), culture conditions (serum-free or serum-containing), manufacturing process, concentration, and route of administration (direct scalp injection, microneedling, or drug delivery). Even under the shared name “stem cell conditioned media,” the actual contents can differ substantially between lots and manufacturers.

When a paper’s conclusion is treated as “the same effect will occur in Japanese patients,” clinical reality often disappoints — and this product-and-condition gap is the largest reason.

Gaps in study conditions (target patients, hair loss type, age)

Overseas study participants are frequently narrowed to a relatively homogeneous group, such as Caucasian males in their 30s to 40s with Norwood II–III AGA. Studies whose primary population is the vertex-first pattern, diffuse AGA, or FAGA (female-pattern hair loss) often seen in Japan are scarce. Differences in follicle density, hair cycle, and androgen sensitivity between ethnicities also mean that when your own condition differs from the study cohort, reproducibility of the reported effect naturally drops.

Differences in preparation and administration protocol

It is uncommon for the exosome preparation or conditioned media used in an overseas study to be obtainable in Japan under an identical specification. Particle count, growth factor cocktail composition, dosing interval, per-session volume, presence or absence of concomitant treatments — change any one of these and clinical outcomes shift. Applying overseas conditioned media evidence directly to a Japanese treatment design can therefore produce the divergence of “it doesn’t work the way the paper says.”

A Practical Lens for Spotting the Three Pitfalls

Pitfall 1: A gap between the study population and your own hair status

Reading only the abstract, it is easy to conclude “hair growth effect confirmed,” but whether that study’s patients (age, sex, progression stage, hair loss type) match your own condition is a point you must always confirm. In particular, female diffuse hair loss and AGA in older adults are areas where overseas evidence is thin to begin with, and extrapolating results from young male AGA to these groups requires caution.

Pitfall 2: The preparation cannot be sourced in Japan

Even when a preparation shows efficacy overseas, it is rarely available at Japanese clinics as-is; in many cases a conditioned media from a different cell source, different lot, and different manufacturing facility is used instead. The basis for expecting “the same result as the paper” therefore depends directly on the sameness of the product specification. When the name matches but the contents differ, the outcome will differ too.

Pitfall 3: Reading the Conflict of Interest (COI) disclosure

In research on biological preparations, studies funded by manufacturers or co-authored by staff at the producing company are not uncommon. The “Conflict of Interest (COI)” section of an academic journal discloses funding sources and involved companies. When you read overseas conditioned media evidence, always take a moment for that line — even that alone shifts how you weight the study. COI is not an automatic disqualifier; it is best treated as a signal that calls for careful interpretation of results.

How Patients Can Read Overseas Evidence

When you see a medical advertisement stating that “efficacy has been proven in the latest overseas papers,” try asking your physician three questions. (1) Is the preparation used in that paper the same cell source, manufacturing facility, and specification as what will be administered to me? (2) Does the study cohort resemble my age, sex, and hair loss type? (3) How are the funding source and COI declared in the paper? Confirming just these three items greatly changes how you engage with overseas conditioned media evidence.

Under Japan’s medical advertising guidelines, unfounded absolutes such as “guaranteed regrowth” or “always effective” are not permitted. For AGA treatment guidelines and dermatological information, referring to Japanese public sources such as the guidelines of the Japanese Dermatological Association alongside the paper helps keep the balance right.

At AVAN TOKYO Ginza, we do not build a one-size-fits-all treatment on overseas papers. Instead, we design care from the patient’s own scalp findings, hair loss pattern, rate of progression, age, and overall health. If you have questions about prior treatments elsewhere or about overseas information you have encountered, please feel free to raise them at your first consultation. You may also find our full list of hair regeneration medicine columns useful.

Summary

Overseas papers on conditioned media and exosomes are undoubtedly a valuable source of information. But to import overseas conditioned media evidence directly into Japanese hair regeneration medicine, you must pass through three pitfalls: (1) the gap between the study population and your own condition, (2) the availability of the preparation used, and (3) conflicts of interest. Rather than being swept along by a single phrase — “it worked overseas” — we hope you will match your own symptoms against your physician’s explanation and reach a decision that fits your real situation.

Frequently Asked Questions

Q. If an exosome therapy showed efficacy overseas, can the same effect be expected in Japan?

The preparation and protocol used in an overseas paper are not identical to the treatment delivered at a Japanese clinic. When cell source, manufacturing facility, delivery method, and frequency of administration differ, outcomes can also differ. “Effective overseas” does not automatically mean “effective for me in Japan,” so please confirm with your treating physician.

Q. What should I confirm when a treatment is explained on the basis of an overseas paper?

We recommend asking your physician three things: whether the study’s population (age, sex, hair loss type) resembles your own condition; whether the preparation used is available in Japan under the identical specification; and whether the paper’s funding source and Conflict of Interest (COI) disclosures are stated.

Q. How should I judge clinics that emphasize “the latest overseas evidence”?

Citing overseas evidence is not in itself a bad thing. But you can gauge credibility by checking (1) which paper is being cited, (2) whether the design is a case report or a comparative trial, and (3) whether results are being over-extended in the pitch. Approach clinics that stress definitive guarantees of effect with caution.

Q. Is domestic evidence for hair treatment with stem cell conditioned media itself sufficient?

At present, high-level comparative trials of hair treatment with stem cell conditioned media are still accumulating worldwide. At the level of case reports and observational studies, benefit is suggested, but the stage has not yet been reached where one can say “it always works.” A realistic stance is to consider it in combination with other treatments, on the premise that individual variation and limits exist.

Q. If a treatment advertised as “MHLW-approved” or “nationally approved” has overseas paper backing, can I trust it?

Under Japan’s Act on the Safety of Regenerative Medicine, a “notification” (todokede) is completely different in meaning from “approval” (shonin) as a pharmaceutical. Hair treatments using conditioned media or exosomes are, in most cases, operated under the third-class regenerative medicine notification system and are not “approved drugs.” The presence or absence of overseas evidence and the domestic legal positioning must be understood as separate matters.

──────────────

Supervising Physician: Dr. Shin Moriwaki

Member, Japan Society of Aesthetic Surgery (JSAS) / Member, American Academy of Aesthetic Medicine

ECFMG Certificate

──────────────

📍AVAN TOKYO 銀座 毛髪再生医療

AVAN TOKYO Ginza Hair Regenerative Medicine

English / 中文 / Tiếng Việt available

Inquiries welcome via DM / LINE / Website / Phone.